Drug Database
PT

PT-003

✓ Approved

Pediatrix Therapeutics · Unknown · Unknown

What is PT-003?

PT-003 is a unknown developed by Pediatrix Therapeutics. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyPediatrix Therapeutics
Drug ClassUnknown
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Pediatrix Therapeutics

Therapeutic Indications

PT-003 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersHypersensitivity✓ Approved

Related Research Articles

PubMedArthroscopy, sports medicine, and rehabilitation2026-07-25

Significant Deficits Are Seen in Extensor Muscle Performance but Not Flexor Muscle Performance 6 Months After Anterior Cruciate Ligament Reconstruction Using a Rectus Femoris Tendon Autograft.

de Barros Alef Cavalcanti Matias ACM, Rêgo Márcio Cabral Fagundes MCF, Oliveira Karinna Sonálya Aires da Costa KSADC, Rêgo Marcelo Cabral Fagundes MCF et al.

To evaluate bilateral isokinetic performance symmetry of knee extensors and flexors 6 months after anterior cruciate ligament reconstruction using a rectus femoris tendon autograft. This retrospective case series included patients consecutively recruited at a single tertiary sports medicine center between January 2023 and July 2024. Inclusion required primary anterior cruciate ligament reconstruction with a rectus femoris autograft, no prior knee surgeries, and a minimum 6-month follow-up; patients with revision or multiligamentous procedures were excluded. Isokinetic testing was performed at 6 months using a computerized dynamometer. The nonoperative limb was tested first, followed by the operative limb. Patients performed 5 maximal effort trials at 60°/s for both extension and flexion. Measured outcomes included peak torque (PT), PT normalized to body weight, angle at PT, total work (TT), and mean power (PM) for both knee extension and flexion. Paired t-tests compared operated and nonoperated limbs. Statistical significance was set at P ≤ .05. Thirty-one male patients (mean age, 26.3 ± 4.7 years) were included, with a mean follow-up of 6.2 ± 0.4 months. At 6 months, the operated limb achieved 71% of contralateral PT and 75% of contralateral PM, with significant deficits in extension PT (P < .001), PT normalized to body weight (P < .001), TT (P  < .001), and PM (P = .002), while no significant difference was found for angle at PT (P = .457). Flexor performance showed near-complete recovery, with the operated limb reaching 93% of contralateral peak torque and 90% of TT, with P = .355, .340, .902, .153, and .316 for PT, PT normalized to body weight, angle at PT, TT, and PM, respectively. At 6 months, anterior cruciate ligament reconstruction with a rectus femoris autograft was associated with complete recovery of knee flexor performance but persistent deficits in knee extensor performance. Level IV, retrospective case series.

PMID 42500145
Read full article →
PubMedSleep medicine2026-07-25

One in three patients with positional obstructive sleep apnea does not benefit from positional therapy: Insights from a home-based trial.

Hackethal Sandra S, Del Forno Manuela M, Riglietti Alessia A, Miano Silvia S et al.

Positional obstructive sleep apnea (POSA) is the most common phenotype of obstructive sleep apnea, yet patient selection for positional therapy (PT) remains suboptimal. With this analysis we aimed to clarify how many patients with POSA may not require PT because they do not habitually sleep supine at home, and how many fail vibrotactile PT despite appropriate indication. We conducted a retrospective observational study of consecutive adults with POSA evaluated at a tertiary sleep center between 2021 and 2024. All patients underwent a home-based trial with a neck-based vibrotactile positional therapy device (Night Shift™), consisting of monitoring mode followed by therapy mode. Outcomes included the proportion of non-supine sleepers at home, failure rate of vibrotactile PT, device compliance and differences in supine sleep time between diagnostic testing and home monitoring. Of 92 screened patients, 74 met inclusion criteria (mean age 60.3 ± 13.2 years; mean AHI 22.9 ± 13.3 events/h). Fifteen percent (11/74) did not habitually sleep supine at home, indicating no clinical need for PT, and an additional 14.8% (11/74) failed vibrotactile PT. Overall, 30% of patients were either unlikely to benefit from PT or failed therapy. Non-response was frequently associated with psychotropic or sedative medication use and neurological or sleep-related comorbidities. A substantial proportion of patients diagnosed with POSA either do not require or fail vibrotactile treatment in real-world conditions. Incorporating a brief home monitoring and therapy trial into routine clinical practice may optimize patient selection, reduce unnecessary costs, and improve personalized management of POSA.

PMID 42497816
Read full article →
PubMedChemical science2026-07-25

Water-mediated interfacial modulation for enhanced selectivity in nitroarene hydrogenation over Pt/Fe2O3 catalysts.

Li Anqi A, Li Lin L, Pan Xiaoli X, Zhuo Hongying H et al.

The selective hydrogenation of nitroarenes containing multiple reducible groups to aromatic amines is of considerable importance in fine chemical synthesis. Despite extensive efforts being devoted to catalyst design, the role of water, ubiquitous as a byproduct and a common solvent in these reactions, remains greatly underexplored. In this work, a well-defined PtNP/Fe2O3-sheet model catalyst, featuring uniformly dispersed Pt nanoparticles (NPs) on the (001) facet of Fe2O3 nanoplates, was synthesized to specifically elucidate the effect of water on nitroarene hydrogenation. The selectivity for 3-aminostyrene exhibits a marked enhancement in the presence of water, reaching over 98% at an optimal 10 vol% water content. Combined kinetic studies, in situ infrared spectroscopy, and density functional theory (DFT) calculations reveal that the competitive water dissociation at the Pt δ+ interfacial sites suppresses both -C[double bond, length as m-dash]C- adsorption and H2 dissociation. This interfacial blocking effect promotes preferential hydrogenation of the nitro-group over the low-valent Fe sites at the Pt-Fe2O3 interface. These findings provide atomic-level insights into the key role of water in modulating catalytic performance, offering a distinctive way of optimizing solvents by leveraging the interfacial blocking of water.

PMID 42499576
Read full article →
PubMedVaccine2026-07-25

Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program.

Tricou Vianney V, Saez-Llorens Xavier X, Kosalaraksa Pope P, Reynales Humberto H et al.

Live-attenuated vaccines can replicate for a transient period post-vaccination and may be associated with symptoms resembling natural infection. The tetravalent dengue vaccine, TAK-003, has undergone extensive preclinical assessment to investigate vaccine RNAemia, viremia, genetic stability, and transmissibility. Here, we investigated the presence of vaccine RNAemia, attenuation loci reversions, and their association with viral-syndrome-like adverse events (AEs) in participants throughout the clinical development program. TAK-003 RNA positive serum samples were evaluated for viral replication and sequenced for reversions. Safety data (solicited AEs within 7/14 days; unsolicited AEs within 28 days) were assessed from a pooled phase 1/2 trial analysis. Participants who experienced febrile illness within 30 days post vaccination in the pivotal phase 3 DEN-301 trial and the phase 2 DEN-313 trial were tested for RNAemia and evaluated for AEs. TAK-003 RNAemia was detected in 441/805 (54.8%) of vaccinees (seronegative: 67.0%; seropositive: 33.0%) in the pooled analysis and in 39 participants with febrile illness from the DEN-301/DEN-313 trials (from 1022 febrile illnesses investigated). RNAemia peaked during the second week post-vaccination and mostly occurred after first dose. Although all four dengue virus (DENV) components were detected, RNAemia was most commonly due to DENV-2. 69 single locus reversions were detected; AEs reported in participants with reversions were generally non-serious, and not indicative of increased symptom severity. Pain at injection site (without RNAemia = 42.0%; RNAemia = 46.8%) and headache (without RNAemia = 36.6%; RNAemia = 37.6%) were the most frequently reported solicited AEs. Incidences of pain, erythema, rash, arthralgia, and fatigue were higher in participants with RNAemia. The incidence of unsolicited AEs was higher in participants with RNAemia (62.4%) than without (52.0%). In the DEN-301/DEN-313 analysis, participants with febrile illness showed a similar pattern of symptoms with and without RNAemia. The presence of RNAemia was associated with transient, mild-to-moderate symptoms, resembling natural infection, which were also observed in the absence of RNAemia.

PMID 42497670
Read full article →
PubMedACS physical chemistry Au2026-07-25

Hydrogen Transfer to Internal Alkynes Using Secondary Amines on Carbon-Supported Noble Metals.

Konieczny Katharina K, Qiu Tianyin T, Menzel Jan Paul JP, Maslack Jacqueline J et al.

The catalytic hydrogen transfer of internal alkynes using carbon-supported noble metals (Pd/C, Pt/C) was systematically studied with various secondary amines, such as indoline (Ind), tetrahydroquinoline (Thq), diisopropylamine ((iPr)2NH)), and, for comparison, diisopropylethylamine ((iPr)2NEt)) as hydrogen donors. The reactions proceeded sequentially, forming (Z)- and (E)-olefins as interim products, having (Z) as a major olefin product, which were sequentially hydrogenated to alkanes. The presence of (E)-alkene isomers was also observed as minor products. Among the tested systems, Pt/C-Ind, Pd/C-Ind, Pt/C-Thq, and Pd/C-Thq exhibited the highest activity and selectivity. Initial reaction rates and activation parameters (activation energy, E a; enthalpy of activation, ΔH ‡; and entropy of activation, ΔS ‡) were determined for these systems. To further elucidate the reaction mechanism, density functional theory (DFT) calculations were performed. The computational results revealed that the balance between adsorption strength and binding energy of reactants and intermediates governs the observed selectivity trends. Notably, the strongly negative activation entropies suggest a rigid, highly ordered transition state, independent of the metal catalyst.

PMID 42500219
Read full article →
PubMedSmart molecules : open access2026-07-25

Redox-responsive dual-drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance.

Yin Xiaolan X, Wang Qi Q, Zhang Ming M, Zhang Cheng C et al.

To overcome cisplatin resistance without increasing systemic toxicity, we rationally elaborated a glutathione-activatable prodrug nanomedicine that chemically co-encapsulates cisplatin and a masked protease. First, a redox-labile succinimide linker (NC-ss-COOH) was covalently grafted onto the ε-amino groups of trypsin to create a "pro-protease" (ssTrypsin) whose catalytic activity is completely silenced in circulation but instantly restored (≥96%) upon cleavage by intratumoral GSH. Simultaneously, cisplatin was stably coordinated to the carboxyl-rich backbone of cRGD-PEG-polyglutamic acid and carboxyl-rich ssTrypsin, forming a polymer-Pt(II) prodrug that prevents premature Pt-GSH adduct formation. These two prodrugs co-self-assemble into potent anti-tumor nanoconstructs that actively target αvβ3/αvβ5-overexpressing tumors. Upon GSH-triggered activation, the dual-drug combination exerts complementary actions: (i) released cisplatin directly damages DNA, while (ii) reactivated trypsin proteolytically degrades all intracellular, cytomembrane, and extracellular proteins as possible (including DNA-repair proteins), collectively re-sensitizing resistant cells. This "prodrug + pro-enzyme" strategy yields a 2.5-fold reduction in IC50 against A2780DDP cells and 77% tumor suppression in vivo, all with minimal off-target toxicity.

PMID 42500704
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about PT-003